Therapeutic antibodies have been extensively used to neutralize bioactive factors, as illustrated by intravitreally administered monoclonals to vascular endothelial growth factor (VEGF) that are effective in treatments of neovascular age-related macular degeneration [71]. The gene discussed is VEGFA; the disease is wet macular degeneration.